Animated Dynamics (AniDyn) Inc., employs patented Motility Contrast Imaging, Tissue Dynamic Spectroscopy, and Tissue Dynamic Spectroscopic Imaging as a new form of Biodynamic Imaging (BDI).
- Phenotypic drug response mapping (phenomic profiling) of tumor tissue for evaluation of chemotherapeutic response
- High-content spectral data on drug mode of action
- Superior lead de-risking for drug discovery using label-free, 3D functional imaging
BDI microscopes coming soon! With the help of NSF SBIR phase I and II funding, Anidyn is developing biodynamic imaging modules for inverted phase/fluorescent microscopes to provide BDI capability for their instruments. Anidyn's acquisition and analytical software will be part of the equipment/software bundle.
Features of Biodynamic Imaging (BDI)
Anidyn's platform technology uses low-coherence digital holography to detect diverse cellular motions inside living tissue in vitro up to 1mm in depth. BDI provides information from a 3D tissue volume that includes a health or viability metric in response to a drug or xenobiotic, a spectral fingerprint for drug mode of action, and an image map of drug effects within different zones of a tissue or tumor. The power of the technology is that the 3D tissue architecture is maintained and testing is conducted in a label-free environment. Thus, the drug effects in 3D cultured tissue or in ex vivo tumor biopsies are a more accurate predictor of in vivo response. The viability metric may be used to follow the response to different drug combinations or sequences over time. The spectral fingerprint is indicative of drug mode of action. Feature vectors can be extracted from the spectogram to provide high-content information. Sub-sampling the spectral fingerprint within different zones of a tumor solves the problem of predicting drug treatment response due to tumor heterogeneity. BDI can map the zones in a tumor biopsy that are responsive or non-responsive to anti-cancer drugs the same day that the biopsy is taken. Drug response mapping provides a basis to choose a drug combination or sequence that will treat the maximum volume of tumor.